Personalized cancer vaccine
Moderna stock, $MRNA, surges over +145% after announcing the first ever positive Phase 3 results for a personalized cancer vaccine.
4/1
1 year:
2 years:
10 years:
- Full data to regulators; possible melanoma approval path
- Trials advance in lung, bladder, kidney cancers
2 years:
- Market entry if approved; custom manufacturing constrains supply
- Lower recurrence in high-risk melanoma via T-cells trained on unique tumor mutations
10 years:
- If broader success, adjuvant tool across solid tumors, reducing metastasis by targeting patient-specific antigens
- Scale and cost will gate real-world impact
4/1